Worth reading
51Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
32.214
Millions of yen (narrowing of operating loss)Wording
Avoiding a definitive answer
How definitive the wording is.Results for this period
First quarter1 January 2026–31 March 2026Non-consolidated (standalone)Japanese GAAPNet Sales147¥ millionYear on year +6.1%Progress 24.5%
Operating profit-232¥ million
Ordinary income-232¥ million
Net income attributable to owners of the parent-233¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share-¥3.31
Financial position at period-end
Total assets1,670¥ million
of which net assets 1,311 ¥ millionEquity ratio 78.0%vs. prior year-end +13.9pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueDrug Discovery Business ¥0 thousand, Drug Discovery Support Business ¥147,162 thousand
Segment profitDrug Discovery Business ¥-174,471 thousand, Drug Discovery Support Business ¥80,520 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥600 million
Operating profitNot disclosed
Ordinary incomeNot disclosed
Net incomeNot disclosed
Revision to Earnings ForecastNo
Annual Dividend Forecast¥0 → ¥0（0.0%）
Factors Behind Changes in Business Performance
Net sales increased by ¥8.462 million. Research and development expenses decreased by ¥29.321 million, mainly because expenses related to clinical development decreased, narrowing each loss.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Material subsequent eventsSome of the 23rd Series Stock Acquisition Rights were exercised, and 1,808,000 common shares were issued. Capital stock and capital surplus each increased by ¥85.668 million, and the total number of issued shares as of 30 April 2026 was 74,459,300.
Impairment lossNo applicable matters
Breakdown of extraordinary income (loss)Extraordinary income None (none in the current first quarter) / Extraordinary loss No
Depreciation and amortization¥2,326 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNone (対象者：Not applicable)
Issued Shares at Period-End72,651,300
Treasury Shares at Period-End22,729
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 January 2026–31 March 2026 |
| Net Sales | ¥147 million (YoY +6.1%) |
| Operating profit | ¥-232 million |
| Ordinary income | ¥-232 million |
| Profit attributable to owners of the parent | ¥-233 million |
| Net income per share | -¥3.31 |
| Equity ratio | End of the current fiscal period 78 / End of previous period 64.1 |
| Total assets | ¥1,670 million |
| Net assets | ¥1,311 million |
| Full-year earnings forecast | Net Sales ¥600 million / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Drug Discovery Business ¥0 thousand, Drug Discovery Support Business ¥147,162 thousand |
| Segment profit | Drug Discovery Business ¥-174,471 thousand, Drug Discovery Support Business ¥80,520 thousand |
| Depreciation and amortization | ¥2,326 thousand |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income None (none in the current first quarter) / Extraordinary loss No |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | Some of the 23rd Series Stock Acquisition Rights were exercised, and 1,808,000 common shares were issued. Capital stock and capital surplus each increased by ¥85.668 million, and the total number of issued shares as of 30 April 2026 was 74,459,300. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | None (対象者：Not applicable) |
| Issued Shares at Period-End | 72,651,300 |
| Treasury Shares at Period-End | 22,729 |
| Factors Behind Changes in Business Performance | Net sales increased by ¥8.462 million. Research and development expenses decreased by ¥29.321 million, mainly because expenses related to clinical development decreased, narrowing each loss. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogChanges in the scope of consolidation
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The deficits in operating loss, ordinary loss and net loss narrowed mainly because expenses related to clinical development recorded during the period decreased from the previous period, resulting in a ¥29.321 million decrease in research and development expenses.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.